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Du Cane Road, London W12 0NN, UK
‘Quantitative studies on tissue transplantation immunity. III. Actively
acquired tolerance’, published in Philosophical Transactions B in 1956 by Peter
Medawar and his colleagues, PhD graduate Leslie Brent and postdoctoral
fellow Rupert Billingham, is a full description of the concept of acquired trans-
plantation tolerance. Their 1953Nature paper (Billingham RE et al. 1953Nature
172, 603–606. (doi:10.1038/172603a0)) had provided initial evidence with
experimental results from a small number of neonatal mice, with mention of
similar findings in chicks. The Philosophical Transactions B 1956 paper is clothed
with an astonishing amount of further experimental detail. It is written in Peter
Medawar’s landmark style: witty, perceptive and full of images that can be
recalled even when details of the supporting information have faded. Those
images are provided not just by a series of 20 colour plates showing skin
graft recipient mice, rats, rabbits, chickens and duck, bearing fur or plumage
of donor origin, but by his choice of metaphor, simile and analogy to express
the questions being addressed and the interpretation of their results, along
with those of relevant published data and his prescient ideas of what the
results might portend. This work influenced both immunology researchers
and clinicians and helped to lay the foundations for successful transplantation
programmes. It led to the award of aNobel prize in 1960 toMedawar, and sub-
sequently to several scientists who advanced these areas. This commentary
was written to celebrate the 350th anniversary of the journal Philosophical
Transactions of the Royal Society.1. Summary of the findings
The story of this work done by Peter Medawar (figure 1) and his colleagues, PhD
graduate Leslie Brent and postdoctoral fellow Rupert Billingham (figure 2), was
sparked by an unexpected result of skin grafting experiments in twin cattle
[1,2]. Medawar’s earlier research had focused on the rejection of skin grafts by
burns patients [3,4], using outbred rabbits to investigate the process [4–7]. This
research identified immune responses characterized by lymphocyte infiltration
of genetically dissimilar grafts (but not of autografts, which healed in and
remained) as being responsible for rejection in both species, and by implication
in others. Subsequent exposure to grafts from the same donor resulted in faster
rejection times, a characteristic of immunological memory. Medawar was later
asked by the Animal Breeding Research organization to determine whether
exchange of skin grafts between cattle twins could distinguish between identical
(monozygotic) and fraternal (dizygotic) pairs. To his surprise, dizygotic aswell as
Figure 1. Peter Medawar in 1960, answering congratulatory letters for his
Nobel Prize.
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2monozygotic recipients retained their test twin grafts, while
still able to reject ‘third party’ grafts from unrelated donors
[1,2].
Through Burnet’s writing on theoretical aspects [8], he
became aware of how immune responses might distinguish
‘self’ from ‘non-self’ (i.e. ‘foreign’). Burnet’s hypothesis was
influenced by a report from Ray Owen (figure 3) that, as
adults, twin cattle had circulating red blood cells (RBCs) bear-
ing genetic markers of both twins [9]. Owing to a shared
placental circulation they became chimaeraswith respect to ery-
thropoietic stem cells (the half-life of RBCs is short, requiring
constant replenishment from stem cells). This type of chimaer-
ism is common in cattle, but rare in twins of other placental
species, including sheep and humans. RBC chimaerism and
weakened immune responses to their parabiotic partners had
been reported in birds by Hasˇek (figure 3) [10,11], who at the
time gave the results a politically expedient interpretation sup-
porting Trofim Lysenko’s views denying attribution to genetic
control, influenced by Lamarck and supported by Stalin.
Reproducing the essential elements of chimaerism in
inbred experimental species appeared to Medawar’s team to
be a perfect way of exploring the effects of early life exposure
to tissues from a genetically dissimilar individual with respect
to immunological responses to non-self antigens. The effects
could then be tested during the recipient’s adult life by grafting
skin from a donor genetically identical to the original tissue
source, and thus address Burnet’s hypothesis.
The short report of their initial findings was published in
Nature [12], with a more extensive account in their landmark
paper in Philosophical Transactions B [13]. The alphabeticalorder of their names in publications was Medawar’s conven-
tion and acknowledgement of their team work. They found
that following the injection of late-stage mouse embryos [13]
or neonates [14] of an inbred strain with cell suspensions
from another strain, test skin grafts placed on them as young
adults were not rejected: a significant proportion of the
recipients had been rendered tolerant indefinitely (‘fully
tolerant’), accepting the foreign grafts as ‘self’ (figure 4). This
was powerful support for Burnet’s ideas, and opened
up the possibility that, akin to induction of protective
immune responses to pathogens by vaccines, introduction of
antigen to an immature immune system was an alternate
path through which tolerance could be acquired through an
immune response.
Tolerance induced in this way was immunologically
specific: test skin grafts from mice of other inbred strains
(‘third party grafts’) were rejected, leaving unaffected the
grafts from the donor-strain whose tissues had been injected
into the embryos. Since various cells, including lymphocytes,
could be used to induce tolerance by injection into embryos
and neonates, it was also clear that the transplantation antigens
on skin were expressed in a wide variety of tissues.
Stability of the tolerant state in these mice was tested by
‘adoptive transfer’ of immuno-competent cells, i.e. injecting
fully tolerant recipients either with lymphocytes from naive
mice of the same strain as the tolerant animal, or with
‘memory’ lymphocytes from mice immunized with tissue
from the strain of the test skin graft donor. These experiments
used the method devised by Avrion Mitchison (figure 3), a
former PhD student of Medawar [15]. The memory lympho-
cytes induced a rapid rejection of previously tolerated grafts,
while rejection occurred more slowly after adoptive transfer
of lymphocytes from naive donors. Susceptibility to rejection
was evidence for the tolerated grafts not having lost expression
of target transplantation antigens, since they were still vulner-
able to attack. This argued against ‘graft adaptation’ as an
explanation for tolerance acquired neonatally.
These experiments demonstrated two further character-
istics: firstly, fully tolerant recipient mice could be said to
show ‘central failure’ of their own response to the tolerated
transplantation antigens (according to Burnet’s theory, caused
by clonal deletion of reactive cells), and secondly, that the
mice had not developed the means of preventing potentially
graft-rejecting lymphocytes transferred into them from becom-
ing effector cells. A rider to this last conclusion was however
considered with respect to partially tolerant mice, i.e. those
who had retained their grafts beyond the normal primary rejec-
tion time, but showed eventual breakdown and slow rejection
of the graft. In the discussion, the possibility was raised that
such mice might have developed a state of regulated balance
of effector cells. In retrospect, this is prescient, but that is a
scenario to be discussed later.
The 1956 paper set the scene for showing that, as with late-
stage fetuses made tolerant by in utero injections of various
tissues from another strain, newborn mice could similarly be
rendered tolerant by intravenous injection of lymphocyte sus-
pensions from the other strain [14] (figure 4). Importantly,
this tolerance could only be induced during the first few days
after birth. This narrow window was followed by a brief ‘null’
period when neither tolerance nor immunity was induced,
while if injections were delayed a few more days the effect
was to enhance immune responsiveness, resulting in more
rapid rejection of test skin grafts.
Figure 2. Leslie Brent, Rupert Billingham and technician Trevor Courtenay at University College London in 1955/1956, working out the intravenous route for the
inoculation of cells into newborn mice. (Image provided by Leslie Brent).
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3The probable role of chimaerism in maintaining tolerance
to the test skin grafts was confirmed in experiments with
chicks injected in ovowith cells from another bird, since eryth-
rocytes in birds are nucleated and retain cell surface expression
of antigens detectable by appropriate antisera (figure 5). Induc-
tion of transplantation tolerance by injection of embryos with
donor cells from another member of the same species was
also found in rabbits and bird species such as ducks, but as
bothwere outbred such experimentsweremore difficult to per-
form, because the donor of the tolerance-inducing tissue had to
be kept alive to provide the test skin graft.
Finally, but only in the discussion of this paper, the essen-
tial paradox of pregnancy was formulated, with speculation
about control mechanisms that allow a fetus, despite expres-
sing foreign paternal transplantation antigens, to remain in
the mother’s uterus during development rather than being
rejected in the way that a skin graft of paternal tissue
would be.
The earlier experiments leading up to their landmark
1956 paper [13], as well as the subsequent clinical and
immunological sides of this scientific story have been tracked
down, with great skill, by Daniel Davis in his recent book, The
histocompatibility gene [16].2. Reception and impact
The Philosophical Transactions B 1956 paper and its Nature 1953
precursor [12,13] were read with great interest by both fellow
immunologists and academic clinicians. These included
Donall Thomas, an American haematologist caring for
patients with bone marrow failure. He obtained evidence in
several of his patients receiving bone marrow allografts of
transient donor bone marrow chimaerism, although these
patients eventually died from their underlying disease [17].
One of his first patients who was given donor bone marrowhad been accidentally exposed to radiation, and others were
suffering from leukaemia for which irradiation and/or che-
motherapy had proved toxic to their haematopoietic stem
cells as well as the tumour. Subsequently, ablative and non-
myeloablative protocols were developed to establish bone
marrow transplant therapy with long-term chimaerism.
The Boston surgeon Joseph Murray (figure 3) and his col-
league Paul Russell, who later spent a sabbatical with
Medawar in London, were also influenced by Medawar’s
findings and knew him personally. Joseph Murray wrote to
me in 2005 following the publication of my memoir of
Peter Medawar, commissioned by the American Journal of
Transplantation [18]. In it he reminisced about his personal
and working relationship with Medawar, and their early
days during which ‘Peter frequently visited the Peter Bent
Brigham Hospital. I still recall taking him on rounds visiting
some of our early experimental renal transplant patients. He
commented that it was the first time he had ever seen trans-
plant patients. In retrospect, it must have been quite different
from visiting mice in cages. Peter was always generous in his
recognition of the contribution of surgeons to Transplantation
Biology, a trait not often found in basic scientists’. Murray
carried out the first genetically non-identical human kidney
transplants (i.e. from a sibling, non-identical dizygotic twin
or an unrelated donor) after successfully transplanting a
therapeutic kidney from one member of a pair of identical
twins (monozygotic) to the other [19]. At that time, it was
known that tolerance could be induced by exposure to appro-
priate doses of foreign protein antigens, but the findings by
Medawar and his small team [12,13] were new: immunologi-
cal tolerance to transplants could also be acquired. This gave
hope for using transplantation as a therapy for end-stage
organ failure. Immunological barriers were still there, since
the neonatal tolerance results reported made clear that even
in experimental mice, susceptibility to tolerance induction
diminished with age.
(b)(a)
(c) (d )
Figure 3. Influences and collaborators. (a) Ray Owen discovered that chimaerism in cattle twins protected RBCs of both animals in each of them; (b) Milan Hasˆek,
a Czech immunologist, friend and colleague of Peter Medawar; (c) Avrion Mitchison, a former student of Medawar’s who pioneered functional cellular and molecular
analyses of T helper cells; (d ) Joseph Murray, who carried out the first human kidney transplants.
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4The kidney transplant field initially made progress by
employing immunosuppressive drugs to overcome rejection
responses in adults. The clinical and experimental work in
Boston attracted the talents of the next generation of transplant
surgeons for training periods and sabbaticals. These included
Roy Calne, who in the 1960s contributed to the development of
immunosuppressive drugs in Boston, later returning to set up
kidney and liver transplantation programmes in Cambridge,UK. Roy recalls a student asking Peter after a lecture (around
1960) whether his experimental findings using mice had any
clinical significance, to which he received the reply, ‘none
whatsoever’. Although reasonable at that time, I suspect that
Medawar’s response may have had layers of meaning:
‘no, not this way’, ‘not yet’ or he was testing the student’s
imagination. Peter himself remained deeply committed to
improving the lot of humans, and jokingly referred to himself
(b)(a)
Figure 4. Mice with skin grafts from genetically dissimilar donors (‘homografts’, now termed ‘allografts’) with differently pigmented skin appendages (fur).
(b)(a)
Figure 5. Homografts (allografts) on birds which were synchorially united to their future donors during embryonic life. (a) White Leghorn cockerel with skin graft
from his Rhode Island Red parabiotic partner; (b) Rhode Island Red hen with skin graft from her White Leghorn partner.
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5as ‘fighting against disease and ignorance’, with a huge smile
on his face.
One thing that influenced the route Medawar and his col-
leagues took was that the first immunosuppressive agents
used for kidney transplantationwere so toxic, understandably,
as they were initially developed for cancer chemotherapy;
immunosuppression was a side-effect. However, the patient
need was desperate, and their use, together with X-irradiation
and cortisone, did prolong the survival of kidney transplants,
to a greater extent than would have been predicted by the con-
current laboratory-based research on animals, a point not lost
on Calne.
Alongside the clinical work, experimental studies aimed
at improving transplantation outcomes were pursued in
experimental dogs, rats and mice in research laboratories of
both basic scientists and academic clinicians, on each side
of the Atlantic and in the antipodes. Medawar had previously
investigated, with Billingham et al. [20], the immunosuppres-
sive effects of cortisone, but clinically cortisone was not
without its own undesirable side effects, so new approaches
were needed.
Medawar’sNobel prize award in 1960was in recognition of
the significance of his 1953 and 1956 papers [12,13] on induc-
tion of transplantation tolerance, experimentally providing
supporting evidence for his co-awardee Burnet’s important
hypothesis on self/non-self discrimination. For Medawar that
work marked not a conclusion, but a way to move forward.
At the end of his Nobel prize speech [21, p. 5], there is a telling
section enumerating important, as yet unanswered ques-
tions raised by the discovery of induced transplantation
tolerance. These throw a very interesting light on the state of
immunological knowledge at that time:Far too much is still uncertain. We do not yet know whether any
one antibody-forming cell is potentially capable of making any
antibody within the organism’s immunological repertoire or
whether the competence of any one such cell is restricted to a
sub-class of the reactions that can be engaged in by the organism
considered as a whole. We do not yet know whether the act of
synthesis undertaken by an antibody-forming cell is strictly and
specifically underwritten by the cell’s genetic make-up or
whether, in J. Lederberg’s terminology, the instructions that
govern that act of synthesis are imparted by the antigen itself.
And if it should be true that the antigen does no more than
choose between one set of preexisting instructions and another,
we still do not know whether those instructions are already pre-
sent in the zygote and therefore part of the legacy of its
descendants, or whether they must be added to mutation, necess-
arily during the course of growth. Finally, we do not even know
whether the antitheses as I have put them are wisely so put or
not. But it is the study of tolerance that has raised these ques-
tions . . . and which, in due course, will make an important
contribution to their answers.Transplantation Immunology was indeed the starting point
for the new branch of cellular immunology, which in turn
contributed appropriate experimental systems for pursuing
the cellular and molecular biological aspects of B- and
T-cell responses.3. Subsequent developments
Peter Medawar remained a key figure in the field, attending
meetings of the Transplantation Society and being elected
president in 1966, as were Rupert Billingham and Leslie
Brent later, when they were chairmen in their respective
departments, Billingham at the University of Pennsylvania,
USA and Brent at St Mary’s Medical School, London. In the
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nology, exploring models for the pathology of two-way
immune responses between mother and fetus. The work
of both Medawar’s and Brent’s laboratories focused on
basic research to develop biological reagents such as anti-
lymphocyte serum (ALS) and to devise new models of
tolerance induction in adult mice. Brent found evidence for
regulatory T cells in mice made tolerant following treatment
with ALS [22]. Medawar investigated the preparation and use
of ALS with the young clinicians who came to his laboratory
to do PhDs ([23,24]). ALS was subsequently incorporated in
some protocols to treat transplant patients and those with
autoimmune disease such as multiple sclerosis, before the
later development of monoclonal antibodies that ALS fore-
shadowed. Indeed, polyclonal ALS is still commonly used
in some clinical programmes.
In the 1980s, several new immunosuppressive drugs were
found as the products of various fungal species and devel-
oped further for clinical use by pharmaceutical companies.
The first of these was cyclosporine (ciclosporin), although it
was to some extent both renal- and hepato-toxic. It was fol-
lowed by tacrolimus and sirolimus, calcineurin and mTor
inhibitors that block activation of T cells. Although these
were less toxic they, like all ‘blanket’ immunosuppressive
agents, put the recipient at risk of developing infections
and some cancers. For this reason, the search for the next gen-
eration of biological reagents with similar, but more selective
effects than ALS, has been pursued by a generation of scien-
tists. This has been based on Milstein & Kohler’s [25]
groundbreaking work on monoclonal antibodies. The aim
has been to introduce appropriate monoclonal antibodies
that could be administered for a limited period of time
under conditions that facilitate the development of donor-
specific tolerance, a highly desirable feature of the neonatal
tolerance described in the Medawar team’s 1953 and 1956
papers [12,13]. This has been achieved experimentally by
Herman Waldmann and his colleagues [26–28], but clinically
it has remained a ‘holy grail’. Although donor-specific toler-
ance has been found in some patients (more frequently with
liver transplants, rarely with kidney transplants), who for
various reasons have stopped taking immunosuppressive
drugs, the critical factors for establishing such ‘gold standard’
tolerance are not yet understood.
Medawar and his team retained contact with the develop-
ing immunological and clinical fields, even in those days
without easy communication networks. I am aware, through
my discussions with Leslie Brent and Avrion Mitchison, as
well as Peter Medawar himself, of their contact with a wide
range of immunologists, including those working in relative
isolation in Prague, particularly Hasˇek, whose results were
rather casually referred to in the landmark paper. Such con-
tacts were taken further when travel to international
meetings there became easier. Hasˇek and Medawar became
good friends despite, or perhaps because of, car journeys
taken together at perilous speed on the Czech roads of that
era, and being subjected to Hasˇek’s ‘bear hug’. In Peter
Medawar’s Nobel speech [21] he gives weight to Hasˇek’s
1950s chicken parabiosis experiments that, like his own con-
temporary ones involving in ovo injection of foreign cells in
chick embryos, resulted in chimaerism and tolerance
[10,11]. Medawar also refers to another result his team
obtained following intravenous injection of lymphocytes
from donors unrelated to the recipients, that of ‘runting’.Runting was reported independently by Morten Simonsen
in 1957 [29], who interpreted the associated splenomegaly
in recipients as an attack by immuncompetent lymphocytes
on the donor of the recipient, i.e. ‘graft-versus-host’ disease.4. Ideas sparked, highways and blind alleys
While publication of the Billingham, Brent and Medawar
papers [12,13] caused much excitement among clinicians
treating end-stage organ failure, it also had profound effects
on the development of immunology. Until that time, the
focus of immunologists was on antibodies (serum immuno-
globulins): the molecular basis of their exquisite antigen
specificity had not yet been discovered, although much was
known about immunoglobulin class-associated functions.
The notion of a cell-mediated immunity that did not involve
lymphocytes working through immunoglobulin was foreign
to many immunologists. Initially Medawar considered it
possible that the lymphocyte-mediated graft rejection he
saw following adoptive transfer might be delivered by anti-
bodies, although in this case the failure to produce the
same effect by injecting serum from immunized mice was dif-
ficult to understand. Thus for him ‘cell-mediated immunity’
was identified with lymphocytes themselves.
Serendipitous results from Jacques Miller’s investigation
of lymphomas opened another door for probing the role of
different categories of lymphocytes. Miller had designed
experiments to test the role of the thymus in virus-induced
lymphogenesis, and discovered that neonatal thymectomy
in mice induced profound immunosuppression. He probed
this both by skin grafting and by immunization with sheep
RBCs to test their ability to make antibodies. These mice
failed to reject skin grafts from another mouse strain and
had a defective antibody response, limited to the IgM class,
to sheep red cells [30]. In parallel, the American clinician
Robert Good reported cases of human babies with profound
immunosuppression following inheritance of recessive genes
associated with the developmental absence of a thymus. They
were on the same track at the same time, in the early 1960s.
While mice, as experimental animals, were more tractable,
the existence of similar findings in patients with mutations
affecting thymic development indicated an important con-
served feature. The role that cells from the thymus (dubbed
‘T cells’) played in graft rejection was also clear in mice carry-
ing the Nude mutation [31]: homozygotes (nu/nu) were
unable to reject skin grafts from genetically different mice.
The question of whether the antibody producing cells were
a separate lymphocyte lineage from those causing graft rejec-
tion and other manifestations of cell-mediated immunity was
further explored by immunologists including Claman and his
colleagues in the USA, [32] and Miller in Australia [33]. It was
also pursued by Mitchison [34] and others working in
London at the National Institute of Medical Research (NIMR),
where Peter Medawar was appointed Director in 1962. This
was 2 years after Medawar and the theoretician Burnet were
awarded their Nobel prize on tolerance. The scientists working
on lymphocyte populations were in contact with each other at
meetings andwere frequent visitors at NIMR. They gave semi-
nars, vigorously discussed results and exchanged reagents.
Their parallel strands of investigation, using a variety of exper-
imental approaches, including in vivo adoptive transfer of
genetically marked cells of each lymphocyte type, separately
(b)(a)
Figure 6. (a) George Snell and (b) Peter Gorer discovered mouse H2 genes. Gorer died before Snell was awarded a Nobel prize for this work.
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7or together, arrived at the same conclusion. Antibody produ-
cing cells originating in the bone marrow (B cells) were an
entirely separable population from the T cells arising in the
thymus. Later work on subpopulations of T cells sprang from
this background.
T helper cells (Th cells) both help B cells to optimize anti-
body responses and drive cell-mediated responses such as
graft rejection. Th cells are also involved in the activation of
another major T lymphocyte type—cytotoxic T cells (Tc cells)
that can kill both engrafted foreign tissues as well as the
body’s own cells when they are infected by virus (see below).
A collaborative approach to scientific research was a way
of life strongly encouraged by Medawar. He continued work-
ing at the bench with his small team to understand further
transplantation-related questions. One of those was the mol-
ecular identity of the target for rejection. His own earlier
work using outbred rabbits, and George Snell and Peter
Gorer’s (figure 6) research in the late 1940s with inbred
mice, had indicated that graft rejection is controlled by a
number of independently segregating loci, with one in mice
being notably stronger than others. This was designated H2
by Snell [35]. Snell’s approach was genetic, generating con-
genic mouse strains each carrying a single polymorphic
histocompatibility locus. Gorer’s [36] important contribution
was to identify the mouse H2 transplantation antigen with
allelic anti-red cell antibodies. These approaches were used
by later mouse geneticists to subdivide the ‘strong’ H2
locus into a series of linked genes. Confirmation of this con-
served genetic feature was found in humans nearly two
decades later by scientists working with serum antibodies
from multiparous women and transplant patients. The hom-
ologous human locus controlling strong rejection responses,
HLA, is also a complex. The term ‘major histocompatibility
complex’, MHC, was coined to identify these homologues
found in all mammalian and many other species, includingbirds and reptiles. Medawar [21] had wanted to obtain
‘pure antigen’ for induction of tolerance using biochemical
approaches. His and Snell’s work on transplantation influ-
enced biochemists like Strominger and Nathenson, who
eventually succeeded in purifying HLA and H2 molecules
and determining their crystal structure [37,38] (figure 7).
At NIMR Medawar turned his attention to investigating
the immunosuppressive qualities of ALS, as mentioned in
the previous section. He encouraged and supported scientists
at the Institute and recruited an additional number working
in disciplines caught up in the spin-out of immunological
ideas and questions. It was a heady time. I joined at the
end of 1968, and started collaborative experiments contribut-
ing to the definition of phenotypically and functionally
different subpopulations of T cells [39–41]. I was caught up
in the ferment inwhichmicrobiologists, cell biologists, physiol-
ogists, biochemists, as well as research clinicians in various
specialities, moved in and out of each other’s laboratories talk-
ing about ideas and results. These conversations continued
during lunch and coffee breaks, and in the bar at the end of
the day. I was encouraged to try new in vitro approaches to
cell-mediated immunity. I went to the National Institutes of
Health (NIH) where I gained experience of growing cytotoxic
T cells (Tc) directed against transplantation antigens in vitro
[42], before the ready availability of growth factors. Analysis
of the Tc cell specificity from such cultures led me to results
that intersected with those of Zinkernagel and Doherty, work-
ing on the other side of theworld on T-cell responses to viruses.
Many immunologists in the 1960s and early 1970s, includ-
ing thoseworking on B cells, regarded questions about how the
B-cell repertoire arose as the main frontier for unravelling
the specificity of immune responses (see Medawar’s Nobel lec-
ture [21]). The antibodies B cells made were accessible from
blood samples, and there was a considerable literature about
their biochemical properties and functions, which could be
T-cell
receptors
see the
peptide
presenting
MHC face
and activate
that T cell
(a) (b)
N
N
C
C
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a2
Figure 7. Solution of the crystal structure of an MHC class I molecule showing the membrane-distal domains, a1 and a2, folded to create the peptide binding groove.
(a) Membrane-distal views of the MHC class I molecule HLA-2 without (upper) and with (lower) a peptide fitting into the groove between the a1 and a2 helices.
(b) Same molecule as a ribbon diagram, wherea3 is the membrane proximal-domain of the MHC class I chain whileb2m is a small independently encoded molecule expressed
at the cell surface in non-covalent association with the MHC class I heavy chain. Adapted from Bjorkman et al. [37], reprinted with permission from Macmillan Publishers Ltd.
rstb.royalsocietypublishing.org
Phil.Trans.R.Soc.B
370:20140382
8investigated following immunization with various antigens.
Certain human plasma cell tumours of B lymphocyte origin
(myelomas) were found to produce large amounts of mono-
clonal antibody, a boon for the biochemistry of that time.
A strain of inbred mice, BALB/c, had been discovered at
NIH by Mike Potter [43] to be susceptible to experimental
induction of plasmacytomas (mouse myelomas) that could
be serially transplanted into recipients of the same strain,
providing a renewable source of monoclonal mouse immuno-
globulins. These tumours showed a range of specificities,
allowing sequence comparison of their immunoglobulin heavy
and light chains. The sequence variants discovered led to specu-
lation about how such differences occurred—was it specified by
their respective immunoglobulin genes (germ line) or bysomatic
mutation?SusumoTonegawa, thenworking inBasle, settled this
question using themolecular biologymethods then being devel-
oped. He published his groundbreaking work on somatic gene
rearrangementof immunoglobulingene segments [44]. Thispro-
cess was shown to occur in individual B-cell precursors as they
mature from pluripotential haemopoietic stem cells and pro-
vides the explanation for the generation of antibody diversity.
These findings then formed a model for identifying the similar
basis of T-cell receptor specificity.
By then another focus of immunological research had
moved to T cells, primed by the cellular definition of trans-
plantation immunity that developed as a direct result of the
Billingham, Brent and Medawar paper [13] and by advances
in immunogenetics, with molecular biology then waiting in
the wings. Work on T-cell subpopulations was carried out
with a variety of antigens, including the targets of delayed-
type hypersensitivity, transplantation and viruses. Rolf
Zinkernagel and Peter Doherty, postdoctoral fellows with
medical backgrounds (human and veterinary, respectively)
working in Gordon Ada’s department in Canberra, were
interested in the pathology of neurological disease. Using
the mouse virus lymphocytic choriomeningitis virus(LCMV) they discovered, when examining the specificity of
LCMV-specific Tc cells, that the target involved both a viral
component and one from the infected mouse cells in which
it was growing [45].
The mouse component appeared to be associated with
transplantation antigens, since only infected cells from mice
with the same MHC (H2) alleles were susceptible to lysis. It
was their hugely imaginative step to propose that the T-cell
receptor recognized two components, separately (two recep-
tors) or together (altered self). They termed this ‘MHC
restriction’, implying that all T cells ‘saw’ their cognate anti-
gens in this way. There was a brief resistance to this idea,
until an increasing number of immunologists looked closely
at the results of their T-cell-mediated responses and discovered
independent confirmation. Those working on the category of
transplantation antigens designated ‘minor histocompatibility
antigens’ (minor H antigens) by Snell were among the first to
provide this confirmation. My laboratory did sowith cytotoxic
T cells directed against a single minor H antigen on the Y
chromosome, HY [46], and in the same year Mike Bevan,
another NIMR alumnus, by then working in the USA, found
it was true with multiple unidentified minor H antigens
encoded by loci scattered throughout the genome [47]. Later,
this was confirmed for single minor H antigens encoded by
autosomal genes scattered throughout the genome [48].
Immunologists investigating cytotoxic T-cell responses to
additional viruses (e.g. influenza, [49]) in mice and humans,
discovered that these Tc cells followed the same MHC pat-
tern, restricted by ubiquitously expressed MHC class I
molecules. Similarly, recognition by Th cell is restricted by
MHC II molecules, whose expression is limited to a smaller
range of cell types. Crucially, these include the cells that pro-
cess and present intracellular antigens (antigen presenting
cells, APC) to Th lymphocytes.
MHC class I and class II molecules are highly polymorphic.
They are encoded by different genes in theMHC. Interestingly,
rstb.royalsocietypublishing.org
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broad tissue distribution of the antigens found by Billingham,
Brent andMedawar in 1956 [13] to be capable of inducing neo-
natal tolerance. We now know that the MHC class I restricting
molecules consist of a single heavy chain, non-covalently
linked at the cell surface with a short chain, beta 2 microglobu-
lin (b2m), folded together to form a groove to accommodate
short peptides (8–11 amino acids) (figure 7). Peptides can be
derived from endogenousmolecules, the source ofminor histo-
compatibility antigens, or virus growing in the cell. These are
the targets recognized by Tc cells.
Crucial information for solving the mystery of how T-cell
receptors recognize two components came from the integration
of two pieces of information. One was the discovery by Alain
Townsend [50] of the short peptide nature of the viral com-
ponent. The second was the X-ray diffraction pattern of the
MHC class I molecule, HLA-A2, crystallized by PamBjorkman
in 1987 [37]. This structure solved the ‘dual receptor’/‘altered
self’ recognition quandary posed by Zinkernagel and Doherty
12 years earlier [45]: both self-MHC and peptide were
presented at the cell surface as a complex for the T-cell receptor
to recognize. Bjorkman’s interpretation of the combined
MHC–peptide crystal structure was extended by finding that
the polymorphic residues of the class I heavy chain lay in its
twomembrane distal domains that formed the peptide binding
groove [51] (figure 7). The subsequent crystal solution of MHC
class II molecules shows their two polymorphic alpha and beta
chains are folded together forming a groove capable of accom-
modating slightly longer peptides. The final pieces in this
molecular jigsaw were provided by solving the crystal
structures of T-cell receptors (TCRs) from Tc and Th cells
restricted by MHC class I or II molecules, respectively, and
those of MHC–peptide–TCR complexes [52].
Immune responses as well as tolerance to transplants are
MHC restricted. T-cell receptors are exquisitely structured to
focus on MHC molecules expressed on the cell surface, class I
for Tc cells and class II for Th cells. Both lymphocyte
subpopulations need to collaborate for effective rejection
responses, like those to molecularly defined MHC class I
and II restricted peptide epitopes of the minor transplan-
tation antigen, HY [53–55].
In addition, sub-classes of T cells with regulatory functions
(Th1, Th2, Th17, Treg, NKT) have now been identified. Most
of these lie within the Th cell, MHC class II-restricted lineage
(e.g. [27,55–57]), although NKT cells use other, non-classical
MHC molecules [58]. The interaction of all T cell types with
cognate antigen associated with its MHC restriction molecule
on APC (particularly dendritic cells) is a key event for instigat-
ing and maintaining effector and regulatory functions.
Regulatory cells have a long and complex history, still being
played out. Understanding the mechanisms of immune
regulation is important for transplantation tolerance.5. Current relevance and progress
Although this level ofdetailmightbe consideredbeyondtheBill-
ingham, Brent and Medawar 1956 paper [13] on induction of
transplantation tolerance, each development described above
occurred as a direct or indirect result of their earlier work.
Does this further defined picture help in solving the transplanta-
tion problem? It does, because the underlying immunological
principles discovered allow for new approaches. The identityand complexity of interactions between cell types, cell surface,
secreted and intracellular molecules has already increased to
an extent that could not be envisaged in 1956. That was a time
before ideas about and techniques for sequencing DNA,
mRNA or RNAi were current, when restriction enzymes had
not been discovered, norDNAmethylation andother epigenetic
controls of gene expression. Transgenesis by somatic or germline
mutation was a distant dream, utopian or dystopian depending
on the view. Imaging was limited to classical light microscopy,
early electron microscopy and X-ray analysis.
During the ensuing decades, clear evidence has built up
that the immune system has evolved under pressure from
rapidly mutating pathogens. It is therefore not surprising
that it includes an astonishing level of degeneracy (confirmed
in many transgenic gene knockout models) to ensure there
are many pathways to keep foreign molecules at bay. Rejec-
tion of potentially therapeutic transplants is a side effect.
Fine control of immune responses employs an array of cell
types, cell-bound accessory molecules, lymphokines and che-
mokines whose function is to orchestrate defence. New
molecules and signalling pathways are still being discovered.
Clinical advances for improved treatment to transplant
patients, as well as those with autoimmune disease and
cancer, need to be viewed against this background. They
are dependent on both clinical skills and new findings.
Some, like the original work on acquired immunity, are
triggered by serendipity.
In the clinical field, transplantation has made unprece-
dented advances in many ways. Hundreds of thousands of
kidney transplants have now been performed worldwide,
some of those also including the pancreas. A somewhat smaller
number of liver transplants, very large numbers of bone
marrow transplants, a significant number of heart and/or
lung transplants and growing numbers of intestinal trans-
plants have also been carried out. Almost all organ (but not
all bone marrow) transplants coming from non-identical
donors require the recipient to receive long-term immunosup-
pression, with its attendant disadvantages. Nevertheless, there
have been significant improvements in the choice of agents,
based on more detailed understanding of molecular pathways
(including antibodies to co-receptors or ligands on T cells or
APC, and drugs binding to key molecules in signalling cas-
cades). Antigen-specific transplantation tolerance remains a
holy grail, to which a small number of apparently stable trans-
plant recipients taken off immunosuppressionmay yield clues,
although that is controversial.
Immunology has tracked into and sparked development
of adjacent fields, beginning with immunogenetics. This in
turn needed molecular biology in its many guises, from
DNA sequencing to expression studies and transgenesis in
increasingly sophisticated forms. Cell biology has developed
alongside, providing a powerful way to look at mechanisms,
but investigations using more complex models are required
to test the in vivo relevance of the findings, ‘in vivo veritas’,
both for transplantation and autoimmunity. Pioneering
work, reminiscent of Medawar’s on ALS [23], has been carried
out by Herman Waldmann and his colleagues on making
monoclonal antibodies (MAb) to mouse, dog and human lym-
phocyte surface molecules. This approach is based on selection
of candidate MAb using in vivo tests in experimental animals,
followed by molecularly humanizing MAb for use in patients
[26–28,57]. It illustrates the need to turn to immunology and
the appropriate use of experimental animals, especially for
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gene and cell therapy. Animal experiments have become more
difficult (and costly), mostly for administrative and legislative
reasons, not all of which are rational, but such research is cru-
cial for progress, both for acquisition of basic knowledge and
for clinical translation.
There are examples of clinical applications going ahead
prematurely, sometimes with disappointing or disastrous
results, through inefficacy and/or unexpected side effects.
Sometimes a hunch has been right, for example, the initial
organ transplants with chemical immunosuppression already
discussed, and the highly successful use of anti-tumour necro-
sis factor (TNF)a monoclonals to treat refractory rheumatoid
arthritis (RA) [59]. In both these cases, there was some evi-
dence for the new treatment (induction of transplantation
tolerance in one, the presence of TNFa among cytokines in
the synovial fluid of RA patients for the other), alongside
knowledge of possible pitfalls. Risk/benefit analysis favoured
action: patients in the 1950s with end-stage kidney failure had
a terminal disease, sufferers from treatment-refractory RA are
in pain and become increasingly disabled. While applauding
these examples, it is essential that scientists and clinicians con-
tinue to design experiments and carry out clinical trials so that
evidence-based decisions can be made.
Meta-analysis is a powerful tool for pulling out rele-
vant factors, especially those relating to clinical treatments.
Systems biology is a maturing field for identifying the most
likely molecules, interactions and pathways from appropriate
clinical and laboratory-generated data. Biostatistics underlies
both, but while carrying out experiments and seeing patients,
the imagination of open minded, creative scientists and clin-
icians often receives clues that provide vital insight about
novel approaches. The work of Billingham, Brent and Meda-
war, and of their closely associated colleagues, attests to
that—they all had a ‘hands on’ approach.6. And the future?
Increased understanding of basic biological processes is crucial
for unravelling the complexity of immune responses to trans-
plants, viruses, tumours and autoantigens. Relevant are
developments in identifying and sequencing molecules of
potential interest and importance, be theyDNA,RNAorprotein.
Advanced technologies are likely to bring new knowledge, pro-
viding the complex interactions between molecules can be
illuminated by both appropriate biostatistics and a sense of rea-
lity-grounded whole-animal physiology. Many scientists and
clinicians share anoptimistic view,while forothers it is tempered
with concerns that this approach generates overwhelming
amounts of data that cloud scientific imagination, and seldom
provide understanding about mechanisms.
Vaccine development has been substantial, with effective
vaccines against many acute infectious diseases such as
mumps, measles, polio, rubella and whooping-cough in near-
universal use. Others remain ‘in development’, either because
the target viruses have evolved various immune escape strat-
egies (for example, human immune deficiency virus, the
cause of AIDS) or the organism is more complex and the best
target molecule(s) and/or the critical protective response may
not have been defined (for example, TB and malaria). Flu vac-
cines necessarily remain in development, as they need to deal
with a virus that can change its makeup on a year-to-yearbasis, both by somatic mutation and by a cut-and-paste mech-
anism using homologous segments of flu viruses from birds
or other species of mammals. The possibility of a pandemic
started in this way is probably more likely than some other
deadly species-hopping viruses, although currently Ebola is
challenging that view. Unravelling the complex nature of pro-
tective responses to pathogens with the interplay between
innate, humoral and cell-mediatedmechanisms requires contin-
ued research if there is to be a rational approach to developing
new preventative and therapeutic approaches.
Effective vaccines against the HPV viruses that can cause
warts and cervical cancer are in prophylactic clinical use in
the western world, but they are needed far more in the devel-
oping world, where the death rate in women from cervical
cancer is disproportionately high. This scenario is also true
for some other virus-related diseases: the need for Epstein
Barr Virus (EBV) vaccine is greater in some African countries,
owing to concurrent parasite diseases, than in the west.
Despite the elimination of smallpox by vaccination, there
have been problems eliminating polio, owing to pockets of
misjudged refusal in certain third world countries. In western
countries, universal childhood vaccination for common and
potentially devastating virus diseases like measles is being
put at risk by lack of objectivity and scaremongering.
In clinical transplantation, there have been reports of some
kidney and liver transplant patients who have been taken off or
have stopped taking their immunosuppressive drugs, never-
theless retaining the graft, although the majority of patients
in this category make rejection responses. For bone marrow
transplant recipients with closely matched donors, clonal del-
etion of donor antigen-specific T cells may occur without
clinically unmanageable graft versus-host disease after repopu-
lation of their haemopoietic system by donor stem cells. Such
patients may be managed successfully without continued
immunosuppression. In this situation, donor cell replacement
may have seeded the thymus, where self-reactive T cells are
removed continuously.
That scenario is unlikely for other organ transplant recipi-
ents unless they have been rendered chimeric following a
bone marrow transplant from the same donor. In this situ-
ation, the patient has bone marrow and a kidney from one
source (the donor) but all the somatic tissues are of recipient
genotype. There are some clinical data on such chimaerism
being successful in kidney graft recipients [60]. An intermedi-
ate state of ‘mixed haematopoietic chimaerism’, in which
there is bone marrow of both donor and recipient origin fol-
lowing much lesser degrees of recipient bone marrow
ablation, has been described in animal models but has not
yet been applied in clinical practice.
Otherwise, individuals who have not undergone dele-
tional tolerance, which is less likely in the absence of bone
marrow cells, even in patients on immunosuppression, are
likely to retain potentially graft-reacting T cells, rather like
the ‘partially tolerant’ mice described by Billingham et al.
[13]. If so, their antigen-specific tolerance would be unstable.
There is controversy about whether or not extensive bio-
marker screening of blood samples from such patients will
reveal a signature of tolerance that could identify those for
whom immunosuppressive drugs could be withdrawn and
which could indicate targets to which other patients could
be manipulated to bring them into a state of tolerance [61].
There may be insufficient data for meaningful analysis of
this outbred population on the stability of these patients’
rstb.royalsociet
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liver transplant patients who appear not to need long-term
immunosuppression [62], and they may be a better source
for determining possible mechanism(s) of graft tolerance. Per-
haps this is the best source for the ‘hope of progress’ that
Medawar espoused. ypublishing.org
Phil.Trans.R.Soc.7. Further reading
The full story of the experiments leading up to their landmark
1956 paper, and the subsequent clinical and immunological
breakthroughs, is discussed by Daniel Davis in his recent
book, The Histocompatibility Gene [16]. His account is informed
not only by published papers and reports, but also from his
interviews with family, friends and colleagues. These include
the surviving member of the trio, Leslie Brent, whose PhDexperiments (thesis now in the archive of the British Transplan-
tation Society), provided much of the data presented in this
landmark paper.
Av Mitchison’s biography of Peter Medawar [63] is
another important source of information.
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